Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifeprunox vs Quetiapine on Weight in Schizophrenia
NCT00396214Phase 3Terminated
- Sponsor
- Solvay
- Start
- Apr 2007
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of bifeprunox in schizophrenia (3 arms), sponsored by Solvay. Primary endpoint: Weight at 8 weeks. Started Apr 2007; status: terminated.
02
Drugs
bifeprunox
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00396214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396214.